文献速递妇科产科

非BRCA及Lynch综合征卵巢癌易感基因致病变异女性风险降低手术的诊疗模式与结局

Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
PubMed 文献 · Gynecol Oncol · 2023-04-06

本研究回顾两机构2000年1月至2019年9月间接受风险降低输卵管卵巢切除术的非BRCA及Lynch综合征相关卵巢癌易感基因致病变异携带者,非BRCA组26例、Lynch组75例,两组均未发现隐匿性卵巢或输卵管癌,Lynch组2例(3%)发现隐匿性子宫内膜癌,术后并发症9/101(9%),尽管绝经症状常见但激素替代治疗使用极少。

要点

  • 非BRCA组26例与Lynch组75例携带者行RRSO后均未发现隐匿性卵巢或输卵管癌。
  • Lynch组2例(3%)发现隐匿性子宫内膜癌,随访期间无患者发生原发性腹膜癌。
  • 术后并发症见于9/101(9%),同时行子宫切除和或结肠手术者出现并发症。

核心结论

  • 两组均未观察到隐匿性卵巢或输卵管癌。
  • 随访期间无复发或原发性妇科相关癌症发生。
  • 尽管绝经症状常见,激素替代治疗使用极少。
  • 两组在行子宫切除和或同期结肠手术时出现手术并发症,提示同期手术应仅在具有指征时施行。

研究设计与样本

  • 经IRB批准的研究,回顾性分析2000年1月至2019年9月在两机构接受RRSO的卵巢癌易感基因致病变异携带者。
  • 纳入非BRCA组26例(BRIP1 9例、RAD51C 9例、RAD51D 8例)和Lynch组75例(MLH1 36例、MSH2 18例、MSH6 21例)。
  • 所有患者在RRSO时均无症状且无恶性肿瘤怀疑,从病历中提取临床病理特征。

主要发现

  • RRSO时中位年龄为47岁。
  • 非BRCA组和Lynch组的中位随访时间分别为18个月和35个月。
  • 非BRCA组无隐匿性卵巢或输卵管癌,Lynch组无隐匿性卵巢或输卵管癌。
  • Lynch组2例(3%)发现隐匿性子宫内膜癌。
  • 术后并发症发生于9/101(9%)患者,非BRCA组报告绝经后症状6/25(23%),Lynch组7/75(37%),激素替代治疗使用极少。

临床怎么用

  • 指南推荐非BRCA及Lynch综合征相关卵巢癌易感基因致病变异女性行风险降低双侧输卵管卵巢切除术(RRSO)。
  • 作者认为,尽管绝经症状常见,激素替代治疗使用极少。
  • 作者认为,同期子宫切除和或结肠手术应仅在具有指征时施行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Guidelines recommend risk-reducing bilateral salpingo-oophorectomy (RRSO) for women with pathogenic variants of non-BRCA and Lynch syndrome-associated ovarian cancer susceptibility genes. Optimal timing and findings at the time of RRSO for these women remains unclear. We sought to characterize practice patterns and frequency of occult gynecologic cancers for these women at our two institutions. METHODS: Women with germline ovarian cancer susceptibility gene pathogenic variants who underwent RRSO between 1/2000-9/2019 were reviewed in an IRB-approved study. All patients were asymptomatic with no suspicion for malignancy at time of RRSO. Clinico-pathologic characteristics were extracted from the medical records. RESULTS: 26 Non-BRCA (9 BRIP1, 9 RAD51C, and 8 RAD51D) and 75 Lynch (36 MLH1, 18 MSH2, 21 MSH6) pathogenic variants carriers were identified. Median age at time of RRSO was 47. There were no occurrences of occult ovarian or fallopian tube cancer in either group. Two patients (3%) in the Lynch group had occult endometrial cancer. Median follow up was 18 and 35 months for non-BRCA and Lynch patients, respectively. No patient developed primary peritoneal cancer upon follow up. Post-surgical complications occurred in 9/101 (9%) of patients. Hormone replacement therapy (HRT) was rarely used despite reported post-menopausal symptoms in 6/25 (23%) and 7/75 (37%) patients, respectively. CONCLUSIONS: No occult ovarian or tubal cancers were observed in either group. No recurrent or primary gynecologic-related cancers occurred upon follow-up. Despite frequent menopausal symptoms, HRT use was rare. Both groups experienced surgical complications when hysterectomy and/or concurrent colon surgery was performed suggesting concurrent surgeries should only be performed when indicated.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Schwartz ZP, Li AJ, Walsh CS, et al. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes. Gynecol Oncol. 2023. PMID: 37030072. doi:10.1016/j.ygyno.2023.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。